Proteona leads international consortium to develop SARS-CoV-2 neutralizing antibody to help vulnerable immunocompromised individuals
with prestigious partners from university hospitals treating COVID-19 patients and leading companies
One more step towards true precision medicine
Proteona Pte. Ltd. announced the “DeepSee” collaboration on developing a platform for patient-derived micro-tumors for drug screening and discovery using single cell multi-omics analysis.
Clinician scientist studying multiple myeloma wins the
first Proteona Oncology Challenge
Proteona Pte. Ltd. has announced the results of the first
Proteona Oncology Challenge, co-sponsored by NovogeneAIT.
Apply now for the Proteona Oncology Challenge using ESCAPE™
single cell proteogenomics analysis.
All scientists and clinicians working to solve major clinical
problems in oncology are welcomed to submit abstracts.
Proteona and AI Singapore partner to improve cell therapy
and IO treatments through single cell analysis of tumors and
CAR T cells
Proteona Pte. Ltd. has announced its participation in AI
Singapore’s 100E programme.
Proteona releases CAR T characterization product based
on ESCAPE™ RNA Sequencing Technology for combined single cell
proteomic and transcriptomic analysis
Proteona announced the launch of its latest
CAR T assay.
Proteona releases ESCAPE™ RNA sequencing for measuring protein
and RNA in single cells with a focus on clinical questions
Proteona launches their first commercial product line, ESCAPE™
RNA Sequencing for clinical ProteoGenomics.
Proteona licenses ESCAPE™ RNA Sequencing Technology for
combined single cell RNA and protein analysis from NUS
Proteona has entered into an exclusive worldwide
licensing agreement with the National University of Singapore (NUS)
for Enhanced Single Cell Analysis with Protein Expression (ESCAPE™)